Phase 1b Study of Dato-DXd in Combination with Immunotherapy with or without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

Trial Identifier: D926FC00001
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo
Start Date: February 2021
Primary Completion Date: April 2026
Study Completion Date: April 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BE Hasselt, BE, 3500
BE Roeselare, BE, 8800
ES A Coruña, ES, 15005
ES Badalona, ES, 08916
ES Barcelona, ES, 8036
ES Madrid, ES, 28034
ES Madrid, ES, 28050
ES Madrid, ES, 28046
ES Sevilla, ES, 41015
IT Aviano, IT, 33081
IT MELDOLA, IT, 47014
IT orbassano, IT, 10043
IT Roma, IT, 00144
JP Koto-ku, JP, 135-8550
JP Sunto-gun, JP, 411-8777
JP Yokohama-shi, JP, 241-8515
PL Gdańsk, PL, 80-952
PL Łódź, PL, 93-338
PL Lublin, PL, 20-090
PL Warszawa, PL, 02-781
TR Adana, TR, 01060
TR Ankara, TR, 06800
TR Ankara, TR, 6200
TR Istanbul, TR, 34010
TR Izmir, TR, 35330
TW Hsinchu, TW, 300
TW Taichung, TW, 40705
TW Tainan, TW, 704
TW Taipei, TW, 100
TW Taipei, TW, 11217
TW Taipei City, TW, 110
TW Taoyuan, TW, 00333
US, CA La Jolla, CA, US, 92093
US, CA Santa Ana, CA, US, 92705
US, MO Saint Louis, MO, US, 63110
US, NJ Hackensack, NJ, US, 07601
US, OH Cleveland, OH, US, 44106
US, PA Philadelphia, PA, US, 19111
US, TX Dallas, TX, US, 75230
US, TX Houston, TX, US, 77030
US, TX San Antonio, TX, US, 78229
US, VA Fairfax, VA, US, 22031